Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR

Michael Mitas, Jonas S. Almeida, Kaidi Mikhitarian, William E. Gillanders, David N. Lewin, Demetri D. Spyropoulos, Loretta Hoover, Amanda Graham, Tammy Glenn, Peter King, David J. Cole, Robert Hawes, Carolyn E. Reed, Brenda J. Hoffman

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Esophageal adenocarcinoma (EA) is increasing faster than any other cancer in the U.S. In this report, we first show that EA can be distinguished from normal esophagus (NE) and esophageal squamous cell carcinoma by plotting expression values for EpCam, TFF1, and SBEM in three-dimensional Euclidean space. For monitoring progression of Barrett's esophagus (BE) to EA, we developed a highly sensitive assay for limited quantities of tissue whereby 50 ng of RNA are first converted to cDNA using 16 gene-specific primers. Using a set of training tissues, we developed a novel quantitative three-tiered algorithm that allows for accurate (overall accuracy = 61/63, 97%) discrimination of BE versus EA tissues using only three genes. The gene used in the first tier of the algorithm is TSPAN: samples not diagnosed as BE or EA by TSPAN in the first tier are then subjected to a second-tier analysis using ECGF1, followed by a third-tier analysis using SPARC. Addition of TFF1 and SBEM to the first tier (i.e., a five-gene marker panel) increases the overall accuracy of the assay to 98% (62/63) and results in mean molecular diagnostic scores (± SD) that are significantly different between EA and BE samples (3.19 ± 1.07 versus -2.74 ± 1.73, respectively). Our results suggest that relatively few genes can be used to monitor progression of BE to EA.

Original languageEnglish (US)
Pages (from-to)2205-2214
Number of pages10
JournalClinical Cancer Research
Volume11
Issue number6
DOIs
StatePublished - Mar 15 2005

Fingerprint

Barrett Esophagus
Reverse Transcription
Adenocarcinoma
Polymerase Chain Reaction
Genes
Molecular Pathology
Esophagus
Complementary DNA
RNA
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. / Mitas, Michael; Almeida, Jonas S.; Mikhitarian, Kaidi; Gillanders, William E.; Lewin, David N.; Spyropoulos, Demetri D.; Hoover, Loretta; Graham, Amanda; Glenn, Tammy; King, Peter; Cole, David J.; Hawes, Robert; Reed, Carolyn E.; Hoffman, Brenda J.

In: Clinical Cancer Research, Vol. 11, No. 6, 15.03.2005, p. 2205-2214.

Research output: Contribution to journalArticle

Mitas, M, Almeida, JS, Mikhitarian, K, Gillanders, WE, Lewin, DN, Spyropoulos, DD, Hoover, L, Graham, A, Glenn, T, King, P, Cole, DJ, Hawes, R, Reed, CE & Hoffman, BJ 2005, 'Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR', Clinical Cancer Research, vol. 11, no. 6, pp. 2205-2214. https://doi.org/10.1158/1078-0432.CCR-04-1091
Mitas, Michael ; Almeida, Jonas S. ; Mikhitarian, Kaidi ; Gillanders, William E. ; Lewin, David N. ; Spyropoulos, Demetri D. ; Hoover, Loretta ; Graham, Amanda ; Glenn, Tammy ; King, Peter ; Cole, David J. ; Hawes, Robert ; Reed, Carolyn E. ; Hoffman, Brenda J. / Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 6. pp. 2205-2214.
@article{4e03534a7e984770949a99f2a84fd2ca,
title = "Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR",
abstract = "Esophageal adenocarcinoma (EA) is increasing faster than any other cancer in the U.S. In this report, we first show that EA can be distinguished from normal esophagus (NE) and esophageal squamous cell carcinoma by plotting expression values for EpCam, TFF1, and SBEM in three-dimensional Euclidean space. For monitoring progression of Barrett's esophagus (BE) to EA, we developed a highly sensitive assay for limited quantities of tissue whereby 50 ng of RNA are first converted to cDNA using 16 gene-specific primers. Using a set of training tissues, we developed a novel quantitative three-tiered algorithm that allows for accurate (overall accuracy = 61/63, 97{\%}) discrimination of BE versus EA tissues using only three genes. The gene used in the first tier of the algorithm is TSPAN: samples not diagnosed as BE or EA by TSPAN in the first tier are then subjected to a second-tier analysis using ECGF1, followed by a third-tier analysis using SPARC. Addition of TFF1 and SBEM to the first tier (i.e., a five-gene marker panel) increases the overall accuracy of the assay to 98{\%} (62/63) and results in mean molecular diagnostic scores (± SD) that are significantly different between EA and BE samples (3.19 ± 1.07 versus -2.74 ± 1.73, respectively). Our results suggest that relatively few genes can be used to monitor progression of BE to EA.",
author = "Michael Mitas and Almeida, {Jonas S.} and Kaidi Mikhitarian and Gillanders, {William E.} and Lewin, {David N.} and Spyropoulos, {Demetri D.} and Loretta Hoover and Amanda Graham and Tammy Glenn and Peter King and Cole, {David J.} and Robert Hawes and Reed, {Carolyn E.} and Hoffman, {Brenda J.}",
year = "2005",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-04-1091",
language = "English (US)",
volume = "11",
pages = "2205--2214",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR

AU - Mitas, Michael

AU - Almeida, Jonas S.

AU - Mikhitarian, Kaidi

AU - Gillanders, William E.

AU - Lewin, David N.

AU - Spyropoulos, Demetri D.

AU - Hoover, Loretta

AU - Graham, Amanda

AU - Glenn, Tammy

AU - King, Peter

AU - Cole, David J.

AU - Hawes, Robert

AU - Reed, Carolyn E.

AU - Hoffman, Brenda J.

PY - 2005/3/15

Y1 - 2005/3/15

N2 - Esophageal adenocarcinoma (EA) is increasing faster than any other cancer in the U.S. In this report, we first show that EA can be distinguished from normal esophagus (NE) and esophageal squamous cell carcinoma by plotting expression values for EpCam, TFF1, and SBEM in three-dimensional Euclidean space. For monitoring progression of Barrett's esophagus (BE) to EA, we developed a highly sensitive assay for limited quantities of tissue whereby 50 ng of RNA are first converted to cDNA using 16 gene-specific primers. Using a set of training tissues, we developed a novel quantitative three-tiered algorithm that allows for accurate (overall accuracy = 61/63, 97%) discrimination of BE versus EA tissues using only three genes. The gene used in the first tier of the algorithm is TSPAN: samples not diagnosed as BE or EA by TSPAN in the first tier are then subjected to a second-tier analysis using ECGF1, followed by a third-tier analysis using SPARC. Addition of TFF1 and SBEM to the first tier (i.e., a five-gene marker panel) increases the overall accuracy of the assay to 98% (62/63) and results in mean molecular diagnostic scores (± SD) that are significantly different between EA and BE samples (3.19 ± 1.07 versus -2.74 ± 1.73, respectively). Our results suggest that relatively few genes can be used to monitor progression of BE to EA.

AB - Esophageal adenocarcinoma (EA) is increasing faster than any other cancer in the U.S. In this report, we first show that EA can be distinguished from normal esophagus (NE) and esophageal squamous cell carcinoma by plotting expression values for EpCam, TFF1, and SBEM in three-dimensional Euclidean space. For monitoring progression of Barrett's esophagus (BE) to EA, we developed a highly sensitive assay for limited quantities of tissue whereby 50 ng of RNA are first converted to cDNA using 16 gene-specific primers. Using a set of training tissues, we developed a novel quantitative three-tiered algorithm that allows for accurate (overall accuracy = 61/63, 97%) discrimination of BE versus EA tissues using only three genes. The gene used in the first tier of the algorithm is TSPAN: samples not diagnosed as BE or EA by TSPAN in the first tier are then subjected to a second-tier analysis using ECGF1, followed by a third-tier analysis using SPARC. Addition of TFF1 and SBEM to the first tier (i.e., a five-gene marker panel) increases the overall accuracy of the assay to 98% (62/63) and results in mean molecular diagnostic scores (± SD) that are significantly different between EA and BE samples (3.19 ± 1.07 versus -2.74 ± 1.73, respectively). Our results suggest that relatively few genes can be used to monitor progression of BE to EA.

UR - http://www.scopus.com/inward/record.url?scp=20144387999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144387999&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-1091

DO - 10.1158/1078-0432.CCR-04-1091

M3 - Article

C2 - 15788668

AN - SCOPUS:20144387999

VL - 11

SP - 2205

EP - 2214

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -